Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
UNIVERSITÄT ZU KÖLN has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 4 distinct examiners and various art units. The distribution shows that each pending matter is being handled by a different examiner, which may lead to independent prosecution timelines for each application. This distribution of 4 pending office actions to the various examiners indicates a decentralized workload across the biotechnology sector.
Madeline Mcguire Dekarske is the busiest examiner for the portfolio, with 1 pending office action. Because of the total pending actions, the workload is distributed such that each of the examiners holds a portion of the cases, making Madeline Mcguire Dekarske 1 of the examiners currently reviewing the university's applications. For practitioners, this means that the action under Madeline Mcguire Dekarske is just as critical as the others. Success in the Biotechnology & Pharmaceuticals area depends on managing these separate examiner relationships.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DEKARSKE, MADELINE MCGUIRE | 1 | 20.0% | +50.0% |
| KANE, TREVOR LOGAN | 1 | 68.8% | +53.3% |
| SALMON, KATHERINE D | 1 | 42.9% | +37.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18725502 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | DEKARSKE, MADELINE MCGUIRE | — |
| 18586191 | TOOL AND METHOD FOR DISAGGREGATION OF POLYQ STRETCH-CONTAINING PROTEINS | KANE, TREVOR LOGAN | — |
| 18681429 | METHOD FOR IDENTIFYING RESPONSIVENESS TO FIBROBLAST GROWTH FACTOR RECEPTOR 1 INHIBITOR THERAPY | SALMON, KATHERINE D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18725502 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | DEKARSKE, MADELINE MCGUIRE | — |
| 18586191 | TOOL AND METHOD FOR DISAGGREGATION OF POLYQ STRETCH-CONTAINING PROTEINS | KANE, TREVOR LOGAN | — |
| 18681429 | METHOD FOR IDENTIFYING RESPONSIVENESS TO FIBROBLAST GROWTH FACTOR RECEPTOR 1 INHIBITOR THERAPY | SALMON, KATHERINE D | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1657 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18725502 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | DEKARSKE, MADELINE MCGUIRE | 1622 | §103§112DP | Non-Final OA | — | Pending | Jun 28, 2024 |
| 18586191 | TOOL AND METHOD FOR DISAGGREGATION OF POLYQ STRETCH-CONTAINING PROTEINS | KANE, TREVOR LOGAN | 1657 | §102§103§112 | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18681429 | METHOD FOR IDENTIFYING RESPONSIVENESS TO FIBROBLAST GROWTH FACTOR RECEPTOR 1 INHIBITOR THERAPY | SALMON, KATHERINE D | 1682 | §101§102§103§112 | Non-Final OA | — | Pending | Feb 05, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITÄT ZU KÖLN has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Madeline Mcguire Dekarske has the most, with 1 of UNIVERSITÄT ZU KÖLN's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
